Analysis of online conversations among health care professionals on social media during August revealed significant support for the first oral treatment for postpartum depression.
The agency approved zuranolone (Zurzuvae, Sage Therapeutics) on Aug. 7.
The analysis also revealed peaks in online conversations among health care professionals (HCPs) surrounding approvals of talquetamab-tgvs (Talvey, Janssen) — indicated for treatment of certain patients with heavily pretreated multiple myeloma — and a single-dose vaccine (Abrysvo, Pfizer) intended to prevent respiratory syncytial virus
